Olympio Metals Hits Solid Gold Intercepts at Quebec Project

Initial Phase 3 assay results from the Bousquet gold project in Quebec returned 5m at 4.54g/t gold, strengthening confidence in the asset.

Justin Tomlinson

Editor-in-Chief, Mora Discover

2 sources
Olympio Metals Hits Solid Gold Intercepts at Quebec Project

Olympio Metals has strengthened confidence in its Bousquet gold project in Quebec following the receipt of initial Phase 3 drilling results. The company continues to build out its gold system in the region on the back of solid drill hits.[1][2]

The first Phase 3 assays from the project returned a solid intercept of 5 meters grading at 4.54 grams per tonne of gold, reinforcing the asset's potential.[1][2]

Edited per Mora's standards.Editorial policyAI disclosureAbout Discover

Related stories

Rolls-Royce and BAE Systems expect higher profits amid defense surge
Rolls-Royce and BAE Systems expect higher profits amid defense surge
The Guardian

Rolls-Royce and BAE Systems expect higher profits amid defense surge

Live, rolling coverage of business, economics and financial markets as investors buy UK defence stocks and await Bank of England interest rate decision That German GDP reading has indeed contributed to the wider eurozone hitting expectations – and then some. The eurozone economy grew by 0.4% in the second quarter of 2026, according to the preliminary reading from Eurostat – defying the gloom caused by the US-Israeli war on Iran. <a href="https://www.theguard

AI sell-off intensifies as investors ditch chip stocks
AI sell-off intensifies as investors ditch chip stocks
The Guardian

AI sell-off intensifies as investors ditch chip stocks

Global markets experienced a sharp sell-off in major AI chipmakers like Samsung and SK Hynix, driving South Korea's stock index to a three-month low. This capital flight highlights growing investor anxiety over high debt levels used to fund aggressive data center expansions and rising Chinese competition. Creators and brands dependent on high-end generative AI tools should audit their software stack now to prepare for potential enterprise price hikes or service pivots if hardware funding tightens.

AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger
AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger
The Guardian

AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger

AstraZeneca is reportedly in talks to acquire US rival Bristol Myers Squibb to create a nearly $400 billion pharmaceutical giant, though a definitive timeline for the deal has not been announced. This massive consolidation will reshape the competitive landscape for oncology and specialty drug marketing, potentially altering corporate sponsor budgets and agency partnerships. Healthcare marketing teams should monitor leadership statements and pipeline announcements to identify early shifts in brand positioning and therapeutic focus.